WEBULL
News
CRDL
1.050
+9.22%
0.089
Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
Canaccord Genuity Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)
TipRanks · 5d ago
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Benzinga · 6d ago
Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
TipRanks · 6d ago
Cardiol Therapeutics Reports Positive Phase II ARCHER Trial Results for CardiolRx™
TipRanks · 6d ago
CARDIOL THERAPEUTICS: NEW DATA FROM PHASE II ARCHER TRIAL DEMONSTRATE CARDIOLRX IMPROVES HEART STRUCTURE IN PATIENTS WITH ACUTE MYOCARDITIS
Reuters · 6d ago
Cardiol Therapeutics Announces New, Comprehensive Data From ARCHER, Randomized Double-Blind, Placebo-Controlled, Multi-Center Phase II Clinical Trial Of CardiolRx In Patients With Acute Myocarditis
Benzinga · 6d ago
Cardiol Therapeutics Reports Phase II Trial Shows CardiolRx Improves Heart Structure in Acute Myocarditis
Reuters · 6d ago
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Newsfile · 6d ago
Weekly Report: what happened at CRDL last week (1124-1128)?
Weekly Report · 6d ago
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress
TipRanks · 11/27 03:57
Weekly Report: what happened at CRDL last week (1117-1121)?
Weekly Report · 11/24 10:13
Cardiol Therapeutics (CRDL) Gets a Buy from Canaccord Genuity
TipRanks · 11/17 12:17
Weekly Report: what happened at CRDL last week (1110-1114)?
Weekly Report · 11/17 10:13
Cardiol Therapeutics: Promising Pipeline and Financial Stability Support Buy Rating
TipRanks · 11/14 16:45
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Benzinga · 11/13 22:35
Cardiol Therapeutics Reports Q3 2025 Financial Results Amidst Cash Decrease
TipRanks · 11/13 22:11
Cardiol Therapeutics posts net loss of $26.6 million for nine months ended September 30, 2025
Reuters · 11/13 21:25
Cardiol Therapeutics Secures U.S. Patent for Heart Drugs
TipRanks · 11/13 13:17
CARDIOL THERAPEUTICS: ONCE ISSUED, THE NEW U.S. PATENT WILL COVER CARDIOLRX™ AND CRD-38 FOR VARIOUS CARDIAC DISORDERS
Reuters · 11/13 13:00
More
Webull provides a variety of real-time CRDL stock news. You can receive the latest news about Cardiol Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About CRDL
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.